- Data presented from clinical and preclinical studies
- Melanocortin agonism reduces stress signaling and resolves
inflammation
- Potential to treat inflammatory diseases without
immunosuppression
CRANBURY, N.J., Oct. 24,
2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE
American: PTN), a biopharmaceutical company developing
first-in-class medicines based on molecules that modulate
the activity of the melanocortin receptor system, presented
a poster titled "Harnessing the Melanocortin System to Heal
Inflammatory Diseases" at the 19th Annual Peptide
Therapeutics Symposium held October 22-23,
2024 in person and virtually in La
Jolla, California. Paul S.
Kayne, Ph.D., lead author and Vice President Biological
Sciences at Palatin Technologies, presented the poster. A copy of
the poster can be found on Palatin's website at www.palatin.com
under Resources.
"The impressive data supports the use of melanocortin agonists
to treat inflammatory diseases safely without immunosuppression,"
said Carl Spana, Ph.D., President
and Chief Executive Officer of Palatin.
The poster presentation illustrates data from clinical and
preclinical studies for three proprietary melanocortin
agonists:
- PL9643 ophthalmic solution demonstrated effectiveness with
statistical significance across multiple clinical signs and reduced
symptomatic ocular pain in the Phase 3 MELODY-1 clinical trial.
This demonstrates that PL9643 has a positive effect across multiple
regions of the eye in patients with moderate and severe dry eye
disease (DED), with an excellent ocular safety/tolerability
profile. PL9643 offers a potentially differentiating efficacy and
safety/tolerability profile from currently available treatments for
DED.
- Oral PL8177 effectively reduced colonic damage and
inflammation, and improved stool consistency and fecal occult blood
in rat animal models of ulcerative colitis (UC). These results were
supported by histopathological analysis and by snRNA-seq data.
PL8177 treatment improved the total colitis index in the rat model
and biased gut macrophages to the anti-inflammatory M2 state in the
same animals. Interim results from an in-progress Phase 2,
double-blind safety and efficacy trial in adult participants with
active UC is expected later this year.
- Subcutaneous BID administration of PL9654 reduced vision loss
and photoreceptor degeneration in the streptozotocin (STZ) rat
model. Genomic and proteomic analysis illustrates that PL9654 0.05
mg/kg causes a reduction in microglia and negative enrichment of
genes associated with immune-related pathways, with a simultaneous
increase in pro-resolution, suggesting a reduction in inflammatory
processes. PL9654 is Palatin's lead development compound for
treating various retinal diseases.
About the Peptide Therapeutics Symposium
The Peptide
Therapeutics Symposium was established in 2005 as an annual
scientific meeting that brings together world leaders in peptide
research from academia and the biopharmaceutical industries. The
meeting focuses on advances in core technology pertinent to
peptide-based drug discovery and therapeutic candidate
development.
About Melanocortin Receptor Agonists and
Inflammation
The melanocortin receptor ("MCR") system has
effects on inflammation, reduction in stress signaling, immune
system responses, metabolism, food intake, and sexual function.
There are five melanocortin receptors, MC1R through MC5R.
Modulation of these receptors, through use of receptor-specific
agonists, which activate receptor function, or receptor-specific
antagonists, which block receptor function, can have medically
significant pharmacological effects. Many tissues and immune cells
located throughout the body, including the gut, kidney and eye,
express melanocortin receptors, empowering our opportunity to
directly activate natural pathways to resolve disease inflammation.
Drugs based on melanocortin agonists have been approved by the FDA
for treating several conditions, including female sexual
dysfunction, inflammatory/autoimmune diseases, and rare forms of
genetic obesity.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com and follow
Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin Technologies, Inc., such as
statements about Palatin products in development, clinical trial
results, potential actions by regulatory agencies including the
FDA, regulatory plans, development programs, proposed indications
for product candidates, and market potential for product candidates
are "forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and as that term is defined in the Private
Securities Litigation Reform Act of 1995. Palatin intends that such
forward-looking statements be subject to the safe harbors created
thereby. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that could cause Palatin's
actual results to be materially different from its historical
results or from any results expressed or implied by such
forward-looking statements. Palatin's actual results may differ
materially from those discussed in the forward-looking statements
for reasons including, but not limited to, results of clinical
trials, regulatory actions by the FDA and other regulatory and the
need for regulatory approvals, Palatin's ability to fund
development of its technology and establish and successfully
complete clinical trials, the length of time and cost required to
complete clinical trials and submit applications for regulatory
approvals, products developed by competing pharmaceutical,
biopharmaceutical and biotechnology companies, commercial
acceptance of Palatin's products, and other factors discussed in
Palatin's periodic filings with the Securities and Exchange
Commission. Palatin is not responsible for updating events that
occur after the date of this press release.
Palatin Technologies® is a registered trademark of
Palatin Technologies, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inflammatory-disease-healing-data-via-palatins-novel-melanocortin-receptor-agonists-presented-at-the-19th-annual-peptide-therapeutics-symposium-302285628.html
SOURCE Palatin Technologies, Inc.